Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raises the price target from $3 to $6.
Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raises the price target from $3 to $6.